Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
stocks
Cutting our fair value on ASX share after poor guidance
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,868.20 | 33.10 | -0.37% |
| CAC 40 | 8,052.51 | 55.92 | -0.69% |
| DAX 40 | 24,162.65 | 116.64 | 0.49% |
| Dow JONES (US) | 47,560.29 | 179.03 | -0.38% |
| FTSE 100 | 9,649.18 | 7.17 | 0.07% |
| HKSE | 25,508.12 | 73.89 | 0.29% |
| NASDAQ | 23,576.49 | 30.58 | 0.13% |
| Nikkei 225 | 50,602.80 | 52.30 | -0.10% |
| NZX 50 Index | 13,371.06 | 83.72 | -0.62% |
| S&P 500 | 6,840.51 | 6.00 | -0.09% |
| S&P/ASX 200 | 8,579.40 | 31.70 | -0.37% |
| SSE Composite Index | 3,900.50 | 9.03 | -0.23% |